✨ Free AI Report
DURECT Corporation: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview DURECT Corporation
Research Preview

DURECT Corporation: Business Overview, Financials & Competitive Analysis

DURECT Corporation is a late-stage biopharmaceutical company engaged in the development of epigenetic therapies that target dysregulated DNA methylation to treat serious and life-threatening conditions, including acut...

Analyst-debate audio for DURECT Corporation

AskCyborg analysts argue the bull and bear cases for DURECT Corporation across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
DURECT Corporation OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
4/ 10Mixed

Cyborg Score thesis

Early-stage epigenetic therapy platform with promising lead candidate but challenged by minimal revenue and dependency on Phase 3...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest DURECT Corporation Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

DURECT Corporation Overview

Pro stress-test →

DURECT Corporation is a late-stage biopharmaceutical company engaged in the development of epigenetic therapies that target dysregulated DNA methylation to treat serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol, is in clinical development for alcoholic hepatitis (AH) with FDA Fast Track and Breakthrough Therapy designations, and is also being explored for metabolic dysfunction-associated steatohepatitis (MASH).

Strategic Profile

Pro stress-test →

The company has a commercial pharmaceutical product, POSIMIR (bupivacaine solution), a non-opioid analgesic utilizing the SABER platform technology. As of September 2025, DURECT operates as a subsidiary of Bausch Health Americas with $12M in cash reserves and has shifted focus to advancing Larsucosterol with a Phase 3 trial estimated at $20M.

Competitive Landscape

Pro stress-test →

DURECT's Larsucosterol targets epigenetic dysregulation in alcoholic hepatitis and MASH, competing in the growing liver disease therapeutic space against companies developing anti-fibrotic and metabolic therapies. The company faces competition from larger pharma and biotech firms with more substantial clinical pipelines and financial resources for Phase 3 trials.

Industry Context

DURECT Corporation operates in Pharmaceuticals.

Key facts

Founded: 1998 · Headquarters: Cupertino, California · Revenue: $2M (2024) · Market cap: N/A

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on DURECT Corporation.

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when DURECT Corporation has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

SelonsertibASK1 inhibitor for fibrosis/cirrhosis (development stage)→ResmetiromThyroid hormone receptor beta agonist for MASH→FibroGenesis PipelineAnti-fibrotic compounds for liver disease→

Compare DURECT Corporation with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

DURECT Corporation operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about DURECT Corporation

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare DURECT Corporation and its top competitor on Cyborg Score”
“What did DURECT Corporation do this quarter?”
“Is DURECT Corporation a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does DURECT Corporation do?+
DURECT Corporation is a late-stage biopharmaceutical company engaged in the development of epigenetic therapies that target dysregulated DNA methylation to treat serious and life-threatening conditions, including acut...
What is DURECT Corporation's Cyborg Score?+
DURECT Corporation has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are DURECT Corporation's main competitors?+
Named competitors include Selonsertib, Resmetirom, FibroGenesis Pipeline. The full competitive landscape is in the AskCyborg report.
How can I get the full DURECT Corporation research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the DURECT Corporation research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track DURECT Corporation over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.